Back to search

Article

Avapritinib is Effective for Treatment of Minimal Residual Disease in Acute Myeloid Leukemia with t (8;21) and KIT mutation Failing to Immunotherapy After Allogeneic Hematopoietic Stem Cell Transplantation

2022-12-03

Abstract excerpt

<title>Abstract</title> <p>In patients with t(8;21) acute myeloid leukemia (AML) with recurrent minimal residual disease (MRD) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), pre-emptive interferon-α therapy and donor lymphocyte infusion are noneffective in 30–50% of patients. Avapritinib is a novel tyrosine kinase inhibitor targeting KIT mutations. We report about 20 patients with t(8;21) A...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
6dfc71f2-017d-537d-9371-df95fef5cb68
DOI
10.21203/rs.3.rs-2317057/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Avapritinib is Effective for Treatment of Minimal Residual Disease in Acute Myeloid Leukemia with t (8;21) and KIT mutation Failing to Immunotherapy After Allogeneic Hematopoietic Stem Cell TransplantationDOI 10.21203/rs.3.rs-2317057/v1
Avapritinib is effective for treatment of minimal residual disease in acute myeloid leukemia with t (8;21) and kit mutation failing to immunotherapy after allogeneic hematopoietic stem cell transplantation.Semantic proximity
Avapritinib monotherapy induces rapid and deep remission of heavily treated, KIT D816H-mutated t(8;21) acute myeloid leukemiaSemantic proximity
Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a case reportSemantic proximity
Pediatric acute myeloid leukemia with t(8;21) and KIT mutation treatment with avapritinib post-stem cell transplantation: a report of four cases.Semantic proximity
Rapid response to avapritinib of acute myeloid leukemia with t(8;21) andKITmutation relapse post allo-HSCTSemantic proximity
[Efficacy and safety analysis of avapritinib in children with RUNX1::RUNX1T1 positive-acute myeloid leukemia with KIT mutations].Semantic proximity
Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation.Semantic proximity
[The efficacy and safety of avapritinib in the treatment of molecular biologically positive core binding factor-acute myeloid leukemia with KIT mutation after allogeneic hematopoietic stem cell transplantation].Semantic proximity
[Analysis of the therapeutic effect of avatinib bridged allogeneic hematopoietic stem cell transplantation on 7 cases of recurrent/refractory RUNX1-RUNX1T1 positive acute myeloid leukemia with KIT mutations].Semantic proximity
Avapritinib for targeting KIT D816V-mutated acute myeloid leukemia relapsed after allogeneic hematopoietic stem cell transplant with extramedullary and central nervous system involvement.Semantic proximity
KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study GroupSemantic proximity
Effects of c-KIT mutations on expression of the RUNX1/RUNX1T1 fusion transcript in t(8;21)-positive acute myeloid leukemia patients.Semantic proximity
Select a neighboring publication to make it the new centre.